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Barriers to effective diagnostic testing for human immunodeficiency virus type 1 (HIV-1) infection can be
reduced with simple, reliable, and rapid detection methods. Our objective was to determine the accuracy,
sensitivity, and specificity of a new rapid, lateral-flow immunochromatographic HIV-1 antibody detection
device. Preclinical studies were performed using seroconversion, cross-reaction, and interference panels,
archived clinical specimens, and fresh whole blood. In a multicenter, prospective clinical trial, a four-sample
matrix of capillary (fingerstick) whole-blood specimens and venous whole blood, plasma, and serum was tested
for HIV-1 antibodies with the Efoora HIV rapid test (Efoora Inc., Buffalo Grove, IL) and compared with an
enzyme immunoassay (EIA) (Abbott Laboratories) licensed by the Food and Drug Administration. Western
blot and nucleic acid test supplemental assays were employed to adjudicate discordant samples. Preclinical
testing of seroconversion panels showed that antibodies were often detected earlier by the rapid test than by
a reference EIA. No significant interference or cross-reactions were observed. Testing of 4,984 archived
specimens yielded a sensitivity of 99.2% and a specificity of 99.7%. A prospective multicenter clinical study with
2,954 adult volunteers demonstrated sensitivity and specificity for the Efoora HIV rapid test of 99.8% (95%
confidence interval [CI], 99.3 and 99.98%) and 99.0% (95% CI, 98.5 and 99.4%), respectively. Reactive rapid
HIV-1 antibody detection was confirmed in 99.6% of those with a known HIV infection (n  939), 5.2% of those
in the high-risk group (n 1,003), and 0.1% of those in the low-risk group (n 1,012). For 21 (0.71%) patients,
there was discordance between the results of the rapid test and the confirmatory EIA/Western blot tests. We
conclude that the Efoora HIV rapid test is a simple, rapid assay for detection of HIV-1 antibodies, with high
sensitivity and specificity compared to a standardized HIV-1 EIA.
With the increasing availability of rapid tests for the detec-
tion of human immunodeficiency virus type 1 (HIV-1) anti-
bodies, the screening of individuals for HIV infection is mov-
ing from laboratories to clinic-based settings (7). The early
versions of these tests were neither easy to run nor particularly
sensitive or specific (3, 19) Recent advances in the use of
lateral-flow immunochromatographic strips and colloidal gold
technology have allowed the development of rapid tests with
very high sensitivity and specificity that are easy to run and can
be used with whole blood (7, 15). Rapid tests for the detection
of antibodies to HIV in serum or plasma are commercially
available and have been recently reviewed (7, 15).
The potential public health benefits of rapid HIV testing are
internationally recognized by the World Health Organization
and in the United States by the Centers for Disease Control
and Prevention (CDC), the Centers for Medicare and Medic-
aid Services, and the Food and Drug Administration (FDA)
(15, 20). There are at least four reasons to promote rapid HIV
testing. First, a change in the paradigm of HIV counseling and
testing would enhance a proactive role in HIV testing. Accord-
ing to the CDC client record database, only 25 to 43% of those
patients who are ultimately determined to be positive and 33 to
48% of those who are negative return for their results if lab-
oratory-based assays are performed. These rates have im-
proved over the years (18) but are still unacceptably low. How-
ever, in clinical settings equipped with rapid HIV testing,
patients can be present to observe the rapid testing, be in-
formed of the result in 30 min, and be counseled immedi-
ately. Second, rapid HIV tests that can use whole-blood sam-
ples are much more efficient than enzyme immunoassay (EIA)
testing in resource-limited settings where supplies (sterile nee-
dles, blood collection tubes, centrifuges, and electricity, etc.)
are scarce and reporting mechanisms cumbersome (9, 21).
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Third, the rapid HIV tests facilitate the initiation and contin-
uation of preemptive antiretroviral therapy for at-risk patients,
such as pregnant women (1, 2, 4, 12, 14) and exposed health-
care workers. Lastly, the availability of new technology that is
simple, inexpensive, accurate, and comparable to or better
than the best laboratory-based EIAs favors the use of these
tests. It has been demonstrated that two rapid tests (from
different manufacturers) run sequentially or concurrently have
sensitivity and specificity equal to those of an EIA and Western
blotting (WB) (8, 17), thus lending support to the concept of
high accuracy with rapid testing.
We report here the preclinical studies and a multicenter
clinical trial that were conducted to determine the accuracy
(i.e., sensitivity and specificity) of a new rapid, lateral-flow
immunochromatographic HIV-1 antibody detection device
compared to traditional tests.
(The preclinical work was presented previously as a poster
by Alzona et al. [Pre-clinical evaluation of a rapid, single-use
test for detection of HIV antibodies in whole blood, abstr.
M28] at the Annual Meeting of the Pan American Society for
Clinical Virology, Clearwater Beach, Fla., 27 to 30 April 2003.
The clinical trial data were presented previously as a poster by
Mundy et al. [Clinical evaluation of an HIV rapid test for
detection of HIV antibodies in fingerstick whole blood] at the
International AIDS Society Meeting, Paris, France, 13 to 16
July 2003.)
MATERIALS AND METHODS
The Efoora HIV rapid test and test principles. The Efoora HIV rapid test is
a unidirectional, lateral-flow immunochromatographic device to which there is
binding and concentration of anti-HIV antibodies to HIV antigens located at the
test line on the device, followed by detection of bound antibodies with colloidal
gold-labeled conjugate (Fig. 1). The plastic housing holds a reagent pad con-
taining an antibody-binding protein conjugated to colloidal gold. The reagent
pad is adjoined to a nitrocellulose membrane that has immobilized HIV antigens
in a striped test zone. In the reagent pad, the specimen’s immunoglobulins bind
to an immunoglobulin binding protein. During migration along the nitrocellulose
membrane, HIV antibodies, if present, bind to HIV antigens and are immobi-
lized for visualization in the test zone via a deposition of colloidal gold carried by
the anti-HIV antibodies. The control zone is reactive in the presence of any
immunoglobulin in the test sample. Thus, a positive result has two lines present
after the 20-minute development period and a negative test has one line (control
line).
Laboratory testing of commercially available panels. These assays were per-
formed between April 2001 and December 2003 at the Efoora laboratory in
Buffalo Grove, Ill., or at other contracted laboratories. Seroconversion panels
(Table 1) were from Boston Biomedica, Inc. (Boston, MA), Serologicals Cor-
poration (Norcross, GA), and Impath-BioClincial Partners (Franklin, MA). HIV
antibodies were spiked by the addition of 10% (vol/vol) HIV-1-positive human
plasma into the samples of interference and cross-reactivity panels (Impath-BCP,
Boston Biomedica, UCLA [Los Angeles, CA], Focus Laboratories [Cypress,
CA], Cambridge Labs [Cambridge, MA], and Teragenix [Ft. Lauderdale, FL])
and assayed with the Efoora HIV rapid test to determine the effects of poten-
tially interfering and cross-reactive substances, such as antibodies to human
T-cell leukemia virus (HTLV), Epstein-Barr virus, varicella-zoster virus, cyto-
megalovirus, hepatitis C virus (HCV), hepatitis B virus (HBV), hepatitis A virus,
herpes simplex virus (HSV), Treponema pallidum, Candida spp., or Toxoplasma
gondii or containing rheumatoid factor or antinuclear antibody.
Testing of archived and preclinical specimens. Three different kit lots of
Efoora HIV rapid tests were used during the course of this testing between
March 1999 and February 2001. All lots were tested prior to use and their
performance verified in-house with a number of HIV-positive specimens, includ-
ing low-titer specimens, dilution panels, and negative specimens. Reference tests
were performed at the site of the preclinical study or at reference laboratories,
utilizing various EIA methods and Western blot analyses (Table 2). Some spec-
imens tested at the various sites were known positives for non-clade B HIV-1,
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FIG. 1. Diagram of the physical and functional components of the
Efoora HIV rapid test. Ag, antigen.
TABLE 1. Seroconversion panels: Efoora rapid test versus FDA-licensed enzyme-linked immunosorbent assay tests,
p24 antigen tests, and the Roche Amplicor Monitor testa
Reference test
Test positivity (in bleed intervals [days]) by panel number (BBI code)
Average
1 (AD) 2 (AF) 3 (AP) 4 (AS) 5 (AT) 6 (P)
Abbott
HIV test RNP 1 1 0 1 0 0.6
HIV-1/2 test 1 0 1 2 0 0 0.67
Genetic Systems
HIV test RNP 2 3 RNP RNP 0 1.67
HIV-1/2 test 0 1 0 RNP RNP 0 0.25
Organon Teknika HIV test 0 1 1 RNP RNP 0 0.5
Abbott p24 Ag test 3 0 2 3 3 1 2.0
Coulter p24 Ag test 3 1 2 3 2 ND 2.2
Roche Amplicor Monitor test 3 1 3 5 4 2 3.2
a In these BBI seroconversion panels, a bleed interval was usually 3 to 6 days (the mean bleed interval was 4.6 days). Negative numbers indicate that the Efoora rapid
test was positive earlier than the reference test. A zero indicates that the Efoora rapid test was positive at the same time as the reference test. Positive numbers indicate
that the Efoora rapid test was positive later than the reference test. RNP, reference not positive for any specimen in the panel; ND, not done; Ag, antigen.
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site 1 were from six countries (the United States, Ivory Coast, Philippines,
Gabon, Brazil, and Trinidad; non-United States samples, 988) and included 18
specimens that were known to be positive for HIV-2 and HIV-1/2, as well as 10
that were known to be group M, non-clade B specimens; specimens at site 3
(Ivory Coast) were from local patients and thus were most likely subtype CRF_02
A/G, which is the predominant circulating recombinant form in West Africa, or
subtype A. Seven specimens were known to be HIV-2 positive and 31 specimens
were known to have dual HIV-1/2 infections. Specimens tested at site 5 (South
Africa) were from local patients and thus were most likely HIV-1 subtype C;
specimens tested at site 6 were mostly United States samples (most likely subtype
B), but 10 were known to be dual HIV-1/2 positive, 2 were known to be HIV-2
positive, and 2 were known to be HIV-1 group O positive. Specimens tested at
sites 2 and 4 were predominantly, if not exclusively, from patients whose infection
originated in the United States and thus were probably subtype B.
Clinical trial study participants and sites. Recruitment, obtaining of consent,
and enrollment of study participants occurred at eight United States study sites.
Sites comprised various types of healthcare facilities for individuals at different
points of care and were designated for the recruitment of three target popula-
tions: (i) participants who were infected with HIV and had prior confirmatory
HIV tests (i.e., recruitment at HIV clinics), (ii) participants who were at low risk
for HIV (i.e., recruitment at general health care facilities with low [1%] HIV
prevalence), and (iii) participants who were at high risk for HIV (i.e., recruit-
ment at sites of high [3%] HIV prevalence or of individuals who reported HIV
risk behaviors as defined by the CDC, such as men who have sex with men,
women who have sex with men who have sex with men, injection drug use, or
other high-risk sexual activity).
The study eligibility criteria included consenting adults of 18 and 55 years
of age. Hosts with non-HIV life-threatening illness or immunosuppression were
excluded. Participants were informed of the rapid test results; pretest counseling
and posttest counseling were performed for all high- and low-risk study partic-
ipants. Follow-up confirmatory test results (see below) were provided to the study
team at each site. Site-specific data were forwarded to a central data repository.
This study underwent institutional review board approval at each site or approval
by a third-party institutional review board if none was available locally.
HIV antibody testing. (i)The Efoora HIV rapid test. HIV-1 antibody detection
was performed with the Efoora HIV rapid test (Efoora, Inc., Buffalo Grove, IL)
with a four-sample matrix of fresh capillary and venous whole blood, plasma
(EDTA anticoagulated), and serum. On-site testing by trained personnel was
performed on fresh capillary (finger stick) and venous whole-blood specimens.
Each site processed venous blood samples and tested serum and plasma by using
the HIV rapid test. Each device was for single use, and results were available
within 20 min.
(ii) Standard HIV antibody testing. Focus Technologies (Cypress, CA) was the
designated central reference lab for the clinical trial. All clinical specimens were
sent for HIV antibody EIA assay testing (Abbott HIV-1/2 EIA) with repeat EIA
and HIV-1 WB (Bio-Rad) performed on all EIA-reactive specimens.
(iii) Resolution of discordant test results. For specimens with discordance
between the Efoora HIV rapid test matrix results and/or the reference EIA/WB
results, the central reference laboratory performed triplicate HIV antibody test-
ing (Abbott and Bio-Rad HIV-1/2 EIA), WB (Bio-Rad), and quantification of
HIV viral RNA by using the Roche Amplicor Monitor assay (nucleic acid testing
[NAT]) on plasma specimens.
For aggregate data analysis of both the Efoora and EIA tests, the multiple test
results (i.e., multiple specimen types for Efoora and replicate tests for EIA) were
combined into an overall determination of the state of being reactive or nonre-
active, based on a majority of the test results for that method. The overall Efoora
test result was then compared with the overall EIA test result for concordance,
and if disagreement remained, HIV-1 WB and NAT supplemental assays were
employed to adjudicate discordant samples. If agreement was found between the
overall Efoora test result and NAT result, then the specimen was categorized as
concordant in the final analysis; however, if the overall Efoora test result was
discordant with the reference, the specimen was categorized as discordant. The
final participant status was defined based on NAT results.
(iv) Data analyses. Site-specific data were evaluated at a central data reposi-
tory. All data were analyzed. Descriptive statistics on all study variables were
provided for the entire cohort, for each site, and for each of the target participant
populations. Estimates and 95% confidence intervals (CI) for the performance
characteristics of the Efoora test on the entire cohort were then calculated.
Performance characteristics included the sensitivities, specificities, positive pre-
dictive values (PPV), and negative predictive values (NPV) of the Efoora HIV
rapid test, both for the overall rapid test result and for each of the four individual
matrices of the Efoora device. Performance characteristics were also estimated
for the Efoora HIV rapid test at each site and for each target participant
population (both overall and for each matrix). All statistical tests were performed
with StatXact version 5.
Clinical testing locations in the Northeast United States were as follows:
Bellevue Hospital, New York, N.Y.; Erie County Medical Center, Buffalo, N.Y.;
and Tapestry Health System, Inc. Northampton, Massachusetts. Clinical testing
locations in the Midwest United States were as follows: Chicago Recovery Alli-
ance, Chicago, Ill.; Howard Brown Health Center, Chicago, Ill.; and Washington
University Medical Center, St. Louis, Mo. Clinical testing locations in the West-
ern United States were as follows: Focus Technologies, Inc., Cypress, Calif., and
UCLA, Los Angeles, Calif.
RESULTS
Preclinical studies. Six HIV seroconversion panels were
used to compare the sensitivity of the Efoora HIV rapid test to
that of FDA-licensed EIA assays (Abbott HIV EIA) (Table 1).
The p24 antigen tests (Abbott and Coulter) and the Roche
Amplicor Monitor test for the detection of HIV RNA were
TABLE 2. Efoora HIV rapid test preclinical testing locations and information
Site Date No. of specimenstested Reference test(s)
a Specimen type(s)
U.S. East Coast March 1999 1,931 Genetic Systems HIV-1/2, Bio-Rad WB Serum
February 2000 291 Genetic Systems HIV-1/2, Genetic Systems
rLAV EIA, Bio-Rad WB
Fresh whole blood
February 2001 528 Genetic Systems HIV-1/2, Bio-Rad WB Serum, plasma, whole blood
U.S. Midwest June 1999 1,076 Genetic Systems HIV-1/2, Abbott HIV-1/2,
Bio-Rad WB
Serum, plasma
Ivory Coast, West Africa June 1999 962 Enzygnost Plus, immunocapture HIV Serum, plasma
South Africa March 2000 150 Genetic Systems HIV-1/2 Serum, plasma, whole blood
a rLAV, recombinant lymphadenopathy-associated virus (HIV-1).
TABLE 3. Assigned HIV risk group categorization of 2,954 study




No. (%) of indicated specimens
HIV EIA reactivea HIV EIA nonreactive
HIV infection (939) 935 (99.6) 4 (0.4)
High-risk HIV (1,003) 52 (5.2) 951 (94.8)
Low-risk HIV (1,012) 1 (0.10) 1,011 (99.9)
Total 988 1,966
a HIV EIA, Abbott.
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used for comparison, since both of these assays were known to
detect their respective analytes prior to the appearance of
antibody in recently infected patients (5). Seroconversion pan-
els had six to nine members (i.e., different bleed times). The
mean bleed interval was 4.8 days (range, 2 to 15 days; standard
deviation, 3.1 days). Across all six panels, the Efoora test was
positive sooner than four of the five reference EIAs (negative
average numbers in the right column of Table 1). In contrast,
the Abbott HIV-1/2 EIA detected HIV antibodies in the six
panels 0.67 bleed intervals sooner than the Efoora rapid test.
The Abbott HIV-1/2 and Efoora tests detected antibody at the
same time in three of the panels; the Abbott test detected
antibody sooner by one bleed interval in two of the panels (no.
1 and 3) and by two bleed intervals in one of the panels (no. 4).
As expected, the antigen assays and the HIV RNA assay were
positive prior to any of the antibody tests (Table 1). The Efoora
rapid test detected HIV antibodies 2.0 bleed intervals after the
Abbott p24 antigen assay, 2.2 bleed intervals after the Coulter
p24 antigen assay and 3.2 bleed intervals after the Roche
Amplicor Monitor assay.
Eleven HIV seroconversion panels were used to compare
the sensitivity of the Efoora HIV rapid test to those of FDA-
licensed EIA assays and Western blot methods (Abbott HIV
EIA and Bio-Rad WB). Seroconversion panels had 5 to 14
members. For 10 of the 11 panels tested, the mean bleed
interval was 4.9 days (range, 2 to 28 days; standard deviation,
3.8 days). Across all 11 panels, the Efoora test was reactive at
the same bleed as or sooner than two of the three reference
EIA methods. Efoora and Abbott EIA detection bleeds were
equivalent for six panels, while Abbott EIA detected antibody
one bleed earlier in 4 of the 11 panels tested. Efoora detection
was observed two bleeds earlier than Abbott EIA detection for
one panel. Efoora results closely correlated with positive re-
sults confirmed in all Western blotting methods.
Collections of samples containing substances that could po-
tentially interfere with the proper development of the test or
control lines were tested. These samples were first tested neat
with both Efoora and the Abbott HIV-1/2 reference test and
found to be HIV negative. Then, they were spiked with one-
tenth of a volume of a human plasma sample known to contain
antibodies to HIV-1 (i.e., the known positive plasma sample
was diluted 1:10 into the potentially interfering sample so that
the resulting mixture was 10% known-positive plasma and 90%
sample with potentially interfering substances). The spiked
samples were mixed and tested again with the Efoora assay.
Panels of samples that were icteric (n  30), lipemic (n  30),
and hemolyzed (n 30) and with high hematocrits (n 14) all
tested negative with Abbott and Efoora kits before the spike,
and all tested positive with Efoora after the addition of HIV
antibodies (data not shown). A panel of samples with low
hematocrits (n  15) all tested negative with Abbott and
Efoora tests before the spike, and one tested negative (no
visible band in the test area) with Efoora after the spike (one
false negative; data not shown). A panel of whole-blood sam-
ples (n  30) tested negative with the Abbott test before the
spike, and 29 of 30 tested negative with the Efoora test before
the spike (i.e., one false positive). The same panel of whole-
blood samples tested with Efoora after the spike yielded 29 of
30 positives (one false negative; data not shown).
A viral coinfection panel (catalog no. PCA201; Boston Bio-
medica Inc.) was used to test for possible interference with the
detection of HIV antibodies due to the presence of coinfec-
tions with HBV, HCV, and/or HTLV. Serum was tested from
patients who were coinfected with HIV-1 and also HBV (n 
7); HBV and HCV (n  4); HCV and HTLV (n  3); and
HBV, HCV, and HTLV (n  2). As negative controls, sera
were tested from patients who were infected with HBV, HCV,
and HTLV (n  5); HBV and HTLV (n  2); or none of the
viruses mention above (n  2). The Efoora results for all 25
specimens were concordant with the reference HIV EIA/WB
results (data not shown).
A cross-reactivity performance panel constructed of serum
or plasma samples from patients infected with various viruses
or infectious agents or having conditions that potentially en-
gender antibody production that may interfere with the HIV
assay was tested. The specimens were positive for antibodies
against HTLV (n  20), Epstein-Barr virus viral capsid anti-
gens (n  10), varicella-zoster virus (n  10), cytomegalovirus
(n 10), HSV type 1 and HSV type 2 (n 10), HCV (n 10),
HBV (n  10), hepatitis A virus (n  10), rheumatoid factor
(n  9), T. pallidum (n  6), toxoplasmosis (n  10), Candida
spp. (n  10), and chlamydia (n  10) and samples from mul-
tiparous females (n 10), patients who have received multiple
transfusions (n  9) and from patients with antinuclear anti-
bodies (n  10). In this set of 164 specimens, all of which were
TABLE 4. Comparison of Efoora HIV rapid test and
standard HIV EIA/WB
Overall test result
No. of participants with or
without infection
HIV infection No HIV infection Total
Efoora test reactive 986 19 1,005
Efoora test nonreactive 2 1,947 1,949
Total 988 1,966 2,954
TABLE 5. Sensitivity and specificity, by the Efoora HIV rapid test, overall and by specimen type, for the entire cohort (n  2,954)a
Matrix Sensitivity estimate (%)(no. detected/no. HIV) Sensitivity 95% CI (%)
Specificity estimate (%)
(no. undetected/no. HIV) Specificity 95% CI (%)
Overall 99.8 (986/988) 99.3, 99.98 99.0 (1,947/1,966) 98.5, 99.4
Fingerstick 99.8 (986/988) 99.3, 99.98 99.2 (1,951/1,966) 98.7, 99.6
Whole blood 99.8 (986/988) 99.3, 99.98 99.2 (1,950/1,966) 98.7, 99.5
Plasma 99.8 (986/988) 99.3, 99.98 99.1 (1,949/1,966) 98.6, 99.5
Serum 99.8 (986/988) 99.3, 99.98 99.2 (1,950/1,966) 98.7, 99.5
a , positive; , negative.
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from patients not infected with HIV, there was one false-pos-
itive result with the Efoora HIV rapid test (data not shown).
For the final step in the preclinical evaluation of the Efoora
HIV rapid test, specimens were tested at several international
sites to assess the sensitivity and specificity of the assay as
performed on a variety of archived or fresh specimens in a
laboratory setting. Table 2 summarizes the locations, test ini-
tiation dates, number of specimens tested, and reference tests
that were used for comparison. Specimens differed in type and
presence of HIV-1 and HIV-2. The testing yielded 1,417 pos-
itive concordant results, 3,544 negative concordant results, 11
Efoora rapid test false-positive results, and 12 Efoora false-
negative results. The overall sensitivity and specificity of the
4,984 specimens using the Efoora rapid HIV test were 99.2%
and 99.7%, respectively.
Clinical studies. From December 2001 through February
2003, 2,954 adult volunteers were screened for HIV infection
with the Efoora rapid HIV test and standard HIV-1 antibody
EIA detection methods. By recruitment status, there were 939
(32%) participants who had HIV infection, 1,003 (34%) who
were at high risk for HIV infection, and 1,012 (34%) who were
at low risk for HIV infection. Confirmatory HIV-1 EIA/WB
testing revealed that 99.5% of the specimens from those with a
known HIV infection were reactive, 5.2% of the specimens
from high-risk participants were reactive, and 0.1% of the
specimens from low-risk participants were reactive (Table 3).
For the overall rapid test analysis, sensitivity was based on 988
(33%) confirmed HIV-positive cases and specificity was based
on 1,966 (67%) confirmed HIV-negative cases. Additionally,
there were 1,005 (34%) Efoora test-positive cases and 1,949
(66%) Efoora test-negative cases who served as the bases for
the overall estimates of predictive values. The predictive values
determined by using the aggregate data were skewed due to
the inclusion in our aggregate population of 939 patients who
were recruited as known positives. Predictive values for the
low-risk (6 and 1,006 test-positive and test-negative cases, re-
spectively) and high-risk (64 and 939 test-positive and test-
negative cases, respectively) populations in this study were
therefore also calculated separately.
Performance characteristics overall. The Efoora HIV rapid
test was reactive for the specimens from 986 of 988 participants
with confirmed HIV infections, for a sensitivity estimate of
99.8% (95% CI, 99.3 to 99.98%) (Table 4, Table 5, and Table
6). The Efoora HIV rapid test was nonreactive for 1,947 of
1,966 participants who were confirmed not to have HIV infec-
tion, for a specificity estimate of 99.0% (95% CI, 98.5 to
99.4%). Per the study definitions, if the majority of the four-
sample matrix test results were discordant with the reference
HIV EIA/WB results, the overall EIA test result, and the NAT
result, the specimen was considered discordant in the final
analysis. The final participant status was determined by the
NAT results. Notably, for 21 (0.71%) participants, there was
discordance between the matrix of rapid HIV tests and the
confirmatory HIV EIA/WB tests. Thirteen high-risk and five
low-risk (n  18) participants had false-positive (reactive)
rapid tests that gave discordant nonreactive HIV EIA/WB
results; there was one known HIV-positive participant whose
rapid test result was reactive but the HIV EIA/WB test was
nonreactive (i.e., a false-positive rapid test), thus accounting
for a total of 19 false positives by the Efoora rapid test (Table
4). Two participants with confirmed HIV by EIA/WB had
false-negative (nonreactive) rapid tests (Table 4).
There were four other participants with nonreactive Efoora
HIV rapid tests, reactive HIV EIA/WB tests, and HIV RNA at
50 copies/ml (via NAT); the rapid test results were concor-
dant with the NAT results. Since the NAT result was the final
arbiter, these were recorded as true rapid test negatives and
were categorized among the total of 1,947 true negatives (Ta-
ble 4). Of note, rapid HIV tests may be negative for hosts on
aggressive antiretroviral therapy (13), and these four patients
may have had results that were confounded by this (data not
available). This Efoora HIV rapid test is intended as a screen-
ing test and will not routinely be used for the testing of hosts
with known HIV infections and who are on antiretroviral ther-
TABLE 6. Positive and negative predictive values by the Efoora HIV rapid test, overall and by specimen type,
for the entire cohort (n  2,954)a
Matrix PPV estimate (%)(no. HIV/no. detected) PPV 95% CI (%)
NPV estimate (%)
(no. HIV/no. undetected) NPV 95% CI (%)
Overall 98.1 (986/1,005) 97.1, 98.9 99.9 (1,947/1,949) 99.6, 99.99
Fingerstick 98.5 (986/1,001) 97.5, 99.2 99.9 (1,951/1,953) 99.6, 99.99
Whole blood 98.4 (986/1,002) 97.4, 99.1 99.9 (1,950/1,952) 99.6, 99.99
Plasma 98.3 (986/1,003) 97.3, 99.0 99.9 (1,949/1,951) 99.6, 99.99
Serum 98.4 (986/1,002) 97.4, 99.1 99.9 (1,950/1,952) 99.6, 99.99
a , positive; , negative.
TABLE 7. Sensitivity and specificity, by the Efoora HIV rapid test, overall and by specimen type,
for the low-risk population only (n  1,012)a
Matrix Sensitivity estimate (%)(no. detected/no. HIV) Sensitivity 95% CI (%)
Specificity estimate
(%) (no. undetected/no. HIV) Specificity 95% CI (%)
Overall 100.0 (1/1) 2.5, 100.0 99.5 (1,006/1,011) 98.9, 99.8
Fingerstick 100.0 (1/1) 2.5, 100.0 99.6 (1,007/1,011) 99.0, 99.9
Whole blood 100.0 (1/1) 2.5, 100.0 99.5 (1,006/1,011) 98.9, 99.8
Plasma 100.0 (1/1) 2.5, 100.0 99.7 (1,008/1,011) 99.1, 99.9
Serum 100.0 (1/1) 2.5, 100.0 99.7 (1,008/1,011) 99.1, 99.9
a , positive; , negative.
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apy. The positive predictive value and negative predictive value
for the aggregate population were estimated to be 98.1% (95%
CI, 97.1 to 98.9%) and 99.9% (95% CI, 99.6 to 99.99%),
respectively. Formal statistical testing for homogeneity of ef-
fects across sites and across populations was not possible, as
some centers enrolled only one specific patient population or
the test characteristics had no variability (e.g., test perfor-
mance of 100%). Informal assessments of the estimates of test
performance across sites and across populations, however, sug-
gest strong consistency and support for pooling data for an
overall analysis.
The overall performance characteristics for all 2,954 partic-
ipants with results of the accuracy for each specimen type are
summarized in Table 5 and Table 6. All specimen types cor-
rectly detected 986 of the 988 specimens determined to be true
positives, for a sensitivity estimate of 99.8% for each specimen
type. When fingerstick whole blood was used in the rapid HIV
test, 1,951 of the 1,966 truly negative participants were cor-
rectly identified, for an overall specificity for that specimen
type of 99.2%. For either whole-blood or serum specimen type,
1,950 negative participants were correctly identified (speci-
ficity, 99.2%), and when plasma was the specimen type,
1,949 negative participants were correctly identified (speci-
ficity, 99.1%).
Performance characteristics in low- and high-risk popula-
tions. There were 1,012 low-risk and 1,003 high-risk study par-
ticipants. One recruited low-risk participant was determined to
be HIV positive by both the rapid test and the reference tests.
All four of the test specimens correctly and independently
recorded this result, as shown in the sensitivity estimate col-
umn (Table 7). Of the 1,011 true-negative low-risk partici-
pants, the fingerstick specimens correctly identified 1,007
cases, whole blood identified 1,006 cases, and plasma and se-
rum each identified 1,008 cases (Table 7, specificity estimate
column), for specificities of 99.5% (whole blood) to 99.7%
(serum and plasma). The estimates of positive and negative
predictive values are shown in Table 8 for the low-risk popu-
lation, and the wide confidence intervals limit the interpreta-
tion of this finding.
Among 1,003 high-risk participants, 52 were HIV positive by
the reference tests, 51 of whom were Efoora rapid test positive
by all four specimen types, for a sensitivity in this population of
98.1% (95% CI, 89.7 to 99.95%) (Table 9). There were 11 false
positives with the fingerstick and whole blood specimens, 12
false positives with the serum specimens, and 13 false positives
with plasma specimens, which resulted in a specificity range
from 98.6% to 98.8% (95% CI, 97.9 to 99.4%) for fingerstick
and whole blood (Table 9). The estimates of positive predictive
values were 79.7% for plasma and 82.3% for fingerstick and
whole blood (Table 10). The estimates of negative predictive
values were 99.9% for all four of the sample types.
DISCUSSION
There is rising international interest in the capability for
rapid, on-site HIV testing with reliable and accurate same-day
results (3, 4). The findings from the studies reported here
suggest that the Efoora HIV rapid test can meet this need in
several health service delivery systems. In this series of studies,
this rapid HIV antibody detection assay performed well with
capillary whole blood, venous whole blood, plasma, and serum
and demonstrated high sensitivity and specificity compared to
a standardized HIV EIA. In addition, the specimens used in
the preclinical and clinical phases of testing represented a
broad spectrum of geographic locations, patient populations,
and HIV types and subtypes, including HIV-2. The test per-
formed well with all four test matrices and on specimens from
diverse populations from around the world.
The evaluation of this rapid test was conducted at a variety
of testing sites and healthcare facilities. Although the device is
intended only for professional use, the implementation of test-
ing is simple and applicable to resource-limited settings. One
of the three currently FDA-licensed tests, the OraQuick test,
has been given the rating of “low complexity” by Clinical Lab-
TABLE 8. Positive and negative predictive values, by the Efoora HIV rapid test, overall and by specimen type,
for the low-risk population only (n  1,012)a
Matrix PPV estimate (%)(no. HIV/no. detected) PPV 95% CI (%)
NPV estimate (%)
(no. HIV/no. undetected) NPV 95% CI (%)
Overall 16.7 (1/6) 0.4, 64.1 100.0 (1,006/1,006) 99.6, 100.0
Fingerstick 20.0 (1/5) 0.5, 71.6 100.0 (1,007/1,007) 99.6, 100.0
Whole blood 16.7 (1/6) 0.4, 64.1 100.0 (1,006/1,006) 99.6, 100.0
Plasma 25.0 (1/4) 0.6, 80.6 100.0 (1,008/1,008) 99.6, 100.0
Serum 25.0 (1/4) 0.6, 80.6 100.0 (1,008/1,008) 99.6, 100.0
a , positive; , negative.
TABLE 9. Sensitivity and specificity, by the Efoora HIV rapid test, overall and by specimen type,
for the high-risk population only (n  1,003)a
Matrix Sensitivity estimate (%)(no. detected/no. HIV) Sensitivity 95% CI (%)
Specificity estimate (%)
(no. undetected/no. HIV) Specificity 95% CI (%)
Overall 98.1 (51/52) 89.7, 99.95 98.6 (938/951) 97.7, 99.3
Fingerstick 98.1 (51/52) 89.7, 99.95 98.8 (940/951) 97.9, 99.4
Whole blood 98.1 (51/52) 89.7, 99.95 98.8 (940/951) 97.9, 99.4
Plasma 98.1 (51/52) 89.7, 99.95 98.6 (938/951) 97.7, 99.3
Serum 98.1 (51/52) 89.7, 99.95 98.7 (939/951) 97.8, 99.4
a , positive; , negative.
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oratories Improvement Act of 1988 and thus has recently re-
ceived “waived status.” Waived status allows the test to be
performed by non-laboratory health care professionals and
provides the option for true point-of-care testing in a clinic,
doctor’s office, or emergency department. The Efoora test is
stored at room temperature, requires no special equipment,
and should be considered for use as a screening device in
clinical and outreach settings. In addition, the Efoora test is a
closed system: the specimen and test diluent are added directly
to the test cartridge and then are completely contained within
the cartridge. Other rapid tests require dilution of the blood
outside the assay or addition of multiple reagents to the assay.
It is anticipated that the Efoora HIV rapid test will soon join
the short list of FDA-licensed rapid HIV tests.
There are at least 25 rapid HIV tests currently available on
the worldwide commercial market, thus affirming international
interest in rapid testing formats (3). HIV testing facilities have
recognized the advantages of rapid testing, the CDC has ac-
tively promoted the use of rapid testing, and the manufacturers
are answering the call for more and better rapid HIV tests
(20).
Furthermore, the widespread use of rapid tests for the de-
tection of HIV antibodies is shifting the paradigm for the
screening of at-risk patients for HIV infection (11, 16). In
developing countries, these rapid tests are the standard assay
for the detection of HIV antibodies. The most common algo-
rithm employs a rapid test for the initial screen and, if the
specimen is nonreactive, the patient is considered uninfected,
counseled as such, and released. If reactive, the specimen is
tested with a rapid test from a different manufacturer than that
of the first test. If the specimen is reactive in the second test,
the patient is considered a confirmed positive and counseled as
such. If the second test is nonreactive, the patient is considered
uninfected and such specimens may be sent to a lab for adju-
dication of the discordant rapid results by further testing (the
CDC has recently recommended that in the United States,
these specimens be further tested with a Western blot or im-
munofluorescent antibody assay) (6). The optimal situation
would be to use the most sensitive rapid assay of the two as the
first or screening test and the most specific rapid assay as the
second or supplemental test, thus assuring that the greatest
possible number of potentially reactive specimens is harvested
with the first test and the fewest possible false reactive speci-
mens are recorded as reactive on the second test.
In developed countries, the algorithm for use of rapid HIV
tests will be different, at least temporarily. Most of our screen-
ing tests will continue to be lab-based, and supplemental test-
ing will be all lab-based for the foreseeable future. However,
the rapid tests will find usefulness, particularly with regard to
needlestick and surgical accident cases and in labor and deliv-
ery clinics (10). In these situations, in which the patient is most
likely captive, the actual testing may be performed either
point-of-care or in the laboratory, if transport to the lab is
expedited. However, in other hospital or clinic-based cases, the
turnaround time (TAT) is very important, since, in one study,
more than half of the patients did not stay for their results
when the mean TAT was 107 min (10). Thus, in situations in
which the patients are not captive, it is important that the test
be performed on-site so as to minimize the TAT and optimize
reporting directly to the patient. The needlestick and labor and
delivery situations require rapid testing for important medical
decisions, such as whether to treat or not treat the recipient of
the needlestick or to treat or not treat the mother in order to
reduce the risk of transmission of HIV to her infant. Other
situations involving rapid HIV testing are less critical in terms
of medical decision making but are nonetheless important in
identifying infected persons and informing them of their infec-
tion so that they can be counseled immediately to modify their
behaviors and lower the risk of transmission to others.
As in all studies, there were recognized limitations in both
the study design and the interpretation of findings. For a select
few participants, linking the tests results with the medical chart
review would have guided the test interpretation, but data were
deidentified at study entry. Notably, the risk-group-specific
predictive values are more meaningful than those for the over-
all population.
The performance characteristics of the Efoora HIV rapid
test were based on a comparison to an FDA-licensed EIA for
the detection of human anti-HIV antibodies to HIV-1. Further
studies are needed to document the performance characteris-
tics of this rapid HIV test for HIV-2, but the indications from
the preclinical testing done in Africa are that this test will
detect antibodies to the non-B subtypes of HIV-1 and also to
HIV-2.
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